Company news

CytomX Therapeutics, Inc. news in 2020

CytomX Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

CytomX Therapeutics Appoints Dr. Mani Mohindru to Board of Directors

December 21, 2020

CytomX Therapeutics to Present Updates on CX-2009 at 2020 San Antonio Breast Cancer Symposium

December 2, 2020

CytomX Therapeutics to Present at Upcoming Investor Conferences

November 10, 2020

CytomX Therapeutics Announces Treatment of First Patient in Phase 2 Expansion Study of CX-2029, an Anti-CD71 Probody Drug Conjugate

November 4, 2020

CytomX Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

November 4, 2020

CytomX Therapeutics to Announce Third Quarter 2020 Financial Results

October 28, 2020

CytomX Therapeutics Announces the Planned Retirement of Chief Scientific Officer, W. Michael Kavanaugh, M.D.

October 5, 2020

CytomX Therapeutics to Participate in Upcoming Healthcare Conferences

September 1, 2020

CytomX Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

August 5, 2020

CytomX Therapeutics to Participate in the 2020 Wedbush PacGrow Healthcare Conference

August 3, 2020

CytomX Therapeutics to Announce Second Quarter 2020 Financial Results

July 27, 2020

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

June 21, 2020

CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program

May 28, 2020

CytomX Therapeutics to Participate at Upcoming Healthcare Conferences

May 27, 2020

CytomX Therapeutics to Host Conference Call and Webcast to Review ASCO ASCO20 Virtual Scientific Program Presentations

May 25, 2020

CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

May 12, 2020

CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

May 6, 2020

CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

May 4, 2020

CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

April 28, 2020

CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

April 27, 2020

CytomX Therapeutics to Announce First Quarter 2020 Financial Results

April 26, 2020

CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

March 29, 2020

CytomX Therapeutics announces appointment of Carlos Campoy as chief financial officer

March 22, 2020

CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

March 22, 2020

CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update

February 26, 2020

CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

February 24, 2020

Bristol-Myers Squibb Advances CytomX Therapeutics’ Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

February 23, 2020

CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results

February 19, 2020

CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer

February 2, 2020

Calls in 2020

Decks in 2020